Inovio Pharmaceuticals (INO) said late Thursday that its China partner for VGX-3100, ApolloBio, revealed that the investigational immunotherapy met its primary efficacy endpoint in a phase 3 trial to treat cervical dysplasia, a precancerous condition that can progress to cervical cancer if left untreated.

The investigational DNA immunotherapy demonstrated overall favorable safety and tolerability profile, the company said.

ApolloBio will use trial results to support future regulatory submission of VGX-3100 in China, according to a statement.

Under the deal with ApolloBio, Inovio will receive up to $20 million upon achieving milestones related to the regulatory approval of the immunotherapy in certain territories, according to the company.